FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection[email protected]2022-01-25T15:10:11+00:00January 25th, 2022|
U.S. Food and Drug Administration Approves Orencia® (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD)[email protected]2022-01-25T15:08:18+00:00January 25th, 2022|
Hidden in Plain Sight: We Already Have the Solution for High Drug Prices[email protected]2022-01-25T15:07:10+00:00January 25th, 2022|
Gilead’s Sacituzumab Govitecan-hziy (TRODELVY) is Now a Preferred Treatment Option, as Early as 2L For mTNBC[email protected]2022-01-25T15:06:31+00:00January 25th, 2022|
Boehringer Ingelheim secures permanent J Code J1448 for COSELA™ (trilaciclib)[email protected]2022-01-25T15:05:57+00:00January 25th, 2022|
Understanding the Biden Administration’s Drug Pricing Plan[email protected]2022-01-25T15:05:26+00:00January 25th, 2022|